Geijigajakyak decoction inhibits the motility and tumorigenesis of colorectal cancer cells

BMC Complementary and Alternative Medicine

Research Article

Kyoung-in Lee¹  Hangun Kim²  Yoo-Seung Ko³  Jeong A Bae³  Soong-in Lee⁴  Kyung Keun Kim⁵ 

[1] Biotechnology Industrialization Center, DongShin University, Naju, Korea;College of Pharmacy, Sunchon National University, Sunchon, Korea;Medical Research Center for Gene Regulation, Chonnam National University Medical School, Kwangju, Korea;Medical Research Center for Gene Regulation, Chonnam National University Medical School, Kwangju, Korea;College of Korean Medicine, DongShin University, Naju, Korea;Medical Research Center for Gene Regulation, Chonnam National University Medical School, Kwangju, Korea;Department of Pharmacology, Chonnam National University Medical School, Hak-Dong 5, Dong-Ku, 61469, Kwangju, Korea;

关键词: Colorectal cancer;    Herbal medicine;    Geijigajakyak decoction;    Cell invasion;    Tumorigenesis;   

DOI  :  10.1186/s12906-016-1281-z

 received in 2016-01-21, accepted in 2016-08-11,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundRecent studies report that inflammatory diseases of the large intestine are associated with colorectal cancer. Geijigajakyak Decoction (GJD) has antispasmodic and anti-inflammatory effects on the gastrointestinal tract. Thus, in light of the connection between chronic bowel inflammation and colorectal cancer (CRC), we asked whether GJD inhibits colorectal tumorigenesis.MethodsThe effects of GJD on the viability and proliferation of CRC cells were evaluated using MTT and BrdU assays, respectively. The motility of CRC cells was examined by a Transwell migration/invasion assay and immunoblot analysis was used to examine the signaling pathways associated with migration. A syngeneic Balb/c mice allograft model, in which CT26 cells were injected into the dorsum, was used to evaluate the anti-tumor effects of GJD in vivo.ResultsGJD had no cytotoxic effects against HCT116 CRC cells, although it did inhibit their proliferation. GJD inhibited the migration of HCT116 cells, and suppressed the invasion of HCT116, Caco2, and CSC221 CRC cells. In addition, GJD downregulated the expression of p-JNK and p-p38 MAPK, which are downstream signaling molecules associated with invasiveness. Furthermore, oral administration of GJD (333 mg/kg, twice a day) inhibited tumor growth in a mouse xenograft model.ConclusionsGJD inhibited the motility of human CRC cells and suppressed tumorigenesis in a mouse model. These results suggest that GJD warrants further study as a potential adjuvant anti-cancer therapy.

【 授权许可】

CC BY   
© The Author(s). 2016